This clinical trial is focused on studying a disease called Multiple Myeloma, which is a type of cancer that affects the blood. The treatment being tested in this study is called HyQvia, which is a solution containing human normal immunoglobulin. This solution is given through an injection under the skin, known as a subcutaneous injection. The purpose of the study is to see if using HyQvia can help reduce the number of infections and early deaths in patients who have recently been diagnosed with multiple myeloma and are not eligible for certain intensive treatments like stem cell transplants.

Participants in the study will receive either HyQvia or a standard treatment, which may include a placebo. The study will last for about a year, during which time researchers will monitor the participants to see how many severe infections occur. Severe infections are those that are more serious and require medical attention. The study will also look at other factors, such as how long participants need to take antibiotics or other medications to treat infections, how often they need to be hospitalized due to infections, and their overall survival rates at six and twelve months after starting the study.

Throughout the study, researchers will also collect information on various aspects of the participants’ health, such as their levels of certain antibodies in the blood, which help fight infections, and their quality of life. This information will help determine how effective HyQvia is in preventing infections in people with multiple myeloma. The study aims to provide valuable insights into improving care for patients with this condition.